Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine

Since the first human cancer cell line, HeLa, was established in the early 1950s, there has been a steady increase in the number and tumor type of available cancer cell line models. Cancer cell lines have made significant contributions to the development of various chemotherapeutic agents. Recent advances in multi-omics technologies have facilitated detailed characterizations of the genomic, transcriptomic, proteomic, and epigenomic profiles of these cancer cell lines. An increasing number of studies employ the power of a cancer cell line panel to provide predictive biomarkers for targeted and cytotoxic agents, including those that are already used in clinical practice. Different types of statistical and machine learning algorithms have been developed to analyze the large-scale data sets that have been produced. However, much work remains to address the discrepancies in drug assay results from different platforms and the frequent failures to translate discoveries from cell line models to the clinic. Nevertheless, continuous expansion of cancer cell line panels should provide unprecedented opportunities to identify new candidate targeted therapies, particularly for the so-called "dark matter" group of cancers, for which pharmacologically tractable driver mutations have not been identified.

[1]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[2]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[3]  Nci Dream Community.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[4]  Francisco J. Sánchez-Rivera,et al.  Rapid modeling of cooperating genetic events in cancer through somatic genome editing , 2014, Nature.

[5]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[6]  R. Bernards,et al.  RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.

[7]  Bjoern Peters,et al.  In vivo RNA interference screens identify regulators of antiviral CD4(+) and CD8(+) T cell differentiation. , 2014, Immunity.

[8]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[9]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[10]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[11]  Thomas D. Wu,et al.  Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer , 2014, Nature Communications.

[12]  Neil O. Carragher,et al.  Quantitative phenotypic and pathway profiling guides rational drug combination strategies , 2014, Front. Pharmacol..

[13]  R. Bernards,et al.  Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. , 2014, Cancer discovery.

[14]  M. Boutros,et al.  A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis , 2014, The EMBO journal.

[15]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[16]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[17]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[18]  R. Epstein.  The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe , 2013, Front. Oncol..

[19]  Michael Peyton,et al.  Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.

[20]  Edwin Wang,et al.  Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. , 2013, Cell reports.

[21]  R. Lothe,et al.  Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.

[22]  Junfeng Xia,et al.  Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance , 2013, Genome research.

[23]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[24]  Mathias Wilhelm,et al.  Global proteome analysis of the NCI-60 cell line panel. , 2013, Cell reports.

[25]  Marc L. Mendillo,et al.  A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. , 2013, Cancer cell.

[26]  P. Meltzer,et al.  The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. , 2013, Cancer research.

[27]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[28]  C. Gedye,et al.  The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel , 2013, Pigment cell & melanoma research.

[29]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[30]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[31]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[32]  Mathukumalli Vidyasagar,et al.  siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens , 2013, Genomics & informatics.

[33]  Ruud H. Brakenhoff,et al.  Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer , 2013, Clinical Cancer Research.

[34]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[35]  W. Bodmer,et al.  Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel , 2012, Proceedings of the National Academy of Sciences.

[36]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[37]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[38]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[39]  Aaron N. Chang,et al.  Functional genomics identifies therapeutic targets for MYC-driven cancer , 2012, Proceedings of the National Academy of Sciences.

[40]  Dexin Kong,et al.  JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. , 2012, Bioorganic & medicinal chemistry.

[41]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[42]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[43]  Kevin R Brown,et al.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.

[44]  Chris Albanese,et al.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.

[45]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[46]  Ji Luo,et al.  A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.

[47]  Jean-Pierre Gillet,et al.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.

[48]  Marketa Zvelebil,et al.  High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing , 2011, Genome Biology.

[49]  J. Mesirov,et al.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.

[50]  A. Ashworth,et al.  Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen , 2011, Proceedings of the National Academy of Sciences.

[51]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[52]  H. Ji,et al.  Establishment and characterization of primary lung cancer cell lines from Chinese population , 2011, Acta Pharmacologica Sinica.

[53]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[54]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[55]  Luc Girard,et al.  Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.

[56]  Benito Munoz,et al.  Towards patient-based cancer therapeutics , 2010, Nature Biotechnology.

[57]  Y. Ishikawa,et al.  Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. , 2010, Cancer research.

[58]  J. Minna,et al.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? , 2010, Lung cancer.

[59]  Joel Greshock,et al.  Molecular target class is predictive of in vitro response profile. , 2010, Cancer research.

[60]  Hans Clevers,et al.  Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[61]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[62]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[63]  Jun Yokota,et al.  A gene‐alteration profile of human lung cancer cell lines , 2009, Human mutation.

[64]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[65]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[66]  Laura Tolosi,et al.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.

[67]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[68]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[69]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[70]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[71]  N. Hacohen,et al.  Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[72]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[73]  Elizabeth Iorns,et al.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.

[74]  Stephen J. Elledge,et al.  Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.

[75]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[76]  C. Beaudry,et al.  Glioma cells on the run – the migratory transcriptome of 10 human glioma cell lines , 2008, BMC Genomics.

[77]  A. Iafrate,et al.  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.

[78]  Yi Guo,et al.  Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. , 2007, Cancer research.

[79]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[80]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[81]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[82]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[83]  Ying Liu,et al.  Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[84]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[85]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[86]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[87]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[88]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. , 2005, The Journal of urology.

[89]  M. Bibby,et al.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[91]  Valerie Speirs,et al.  Breast cancer cell lines: friend or foe? , 2003, Breast Cancer Research.

[92]  J. Masters.  HeLa cells 50 years on: the good, the bad and the ugly , 2002, Nature Reviews Cancer.

[93]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[94]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[95]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[96]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[97]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[98]  H. Green,et al.  Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell is , 1975, Cell.

[99]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[100]  B. Dutrillaux,et al.  Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. , 2007, Cancer research.

[101]  J. Minna,et al.  NCI series of cell lines: An historical perspective , 1996, Journal of cellular biochemistry. Supplement.

[102]  A. Gazdar,et al.  Cell culture methods for the establishment of the NCI series of lung cancer cell lines , 1996, Journal of cellular biochemistry. Supplement.

[103]  H Green,et al.  Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. , 1975, Cell.